Levels of soluble complement regulators predict severity of COVID-19 symptoms
Copyright © 2022 Tierney, Alali, Scott, Rees-Unwin, CITIID-NIHR BioResource COVID-19 Collaboration, Clark and Unwin..
The SARS-CoV-2 virus continues to cause significant morbidity and mortality worldwide from COVID-19. One of the major challenges of patient management is the broad range of symptoms observed. While the majority of individuals experience relatively mild disease, a significant minority of patients require hospitalisation, with COVID-19 still proving fatal for some. As such, there remains a desperate need to better understand what drives this severe disease, both in terms of the underlying biology, but also to potentially predict at diagnosis which patients are likely to require further interventions, thus enabling better outcomes for both patients and healthcare systems. Several lines of evidence have pointed to dysregulation of the complement cascade as a major factor in severe COVID-19 outcomes. How this is underpinned mechanistically is not known. Here, we have focussed on the role of the soluble complement regulators Complement Factor H (FH), its splice variant Factor H-like 1 (FHL-1) and five Factor H-Related proteins (FHR1-5). Using a targeted mass spectrometry approach, we quantified these proteins in a cohort of 188 plasma samples from controls and SARS-CoV-2 patients taken at diagnosis. This analysis revealed significant elevations in all FHR proteins, but not FH, in patients with more severe disease, particularly FHR2 and FHR5 (FHR2: 1.97-fold, p<0.0001; FHR5: 2.4-fold, p<0.0001). Furthermore, for a subset of 77 SARS-CoV-2 +ve patients we also analysed time course samples taken approximately 28 days post-diagnosis. Here, we see complement regulator levels drop in all individuals with asymptomatic or mild disease, but regulators remain high in those with more severe outcomes, with elevations in FHR2 over baseline levels in this group. These data support the hypothesis that elevation of circulating levels of the FHR family of proteins could predict disease severity in COVID-19 patients, and that the duration of elevation (or lack of immune activation resolution) may be partly responsible for driving poor outcomes in COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 13(2022) vom: 04., Seite 1032331 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tierney, Anna L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
80295-65-4 |
|---|
| Anmerkungen: |
Date Completed 07.11.2022 Date Revised 29.03.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2022.1032331 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34844446X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34844446X | ||
| 003 | DE-627 | ||
| 005 | 20231226205514.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.1032331 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM34844446X | ||
| 035 | |a (NLM)36330526 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tierney, Anna L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Levels of soluble complement regulators predict severity of COVID-19 symptoms |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2022 | ||
| 500 | |a Date Revised 29.03.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Tierney, Alali, Scott, Rees-Unwin, CITIID-NIHR BioResource COVID-19 Collaboration, Clark and Unwin. | ||
| 520 | |a The SARS-CoV-2 virus continues to cause significant morbidity and mortality worldwide from COVID-19. One of the major challenges of patient management is the broad range of symptoms observed. While the majority of individuals experience relatively mild disease, a significant minority of patients require hospitalisation, with COVID-19 still proving fatal for some. As such, there remains a desperate need to better understand what drives this severe disease, both in terms of the underlying biology, but also to potentially predict at diagnosis which patients are likely to require further interventions, thus enabling better outcomes for both patients and healthcare systems. Several lines of evidence have pointed to dysregulation of the complement cascade as a major factor in severe COVID-19 outcomes. How this is underpinned mechanistically is not known. Here, we have focussed on the role of the soluble complement regulators Complement Factor H (FH), its splice variant Factor H-like 1 (FHL-1) and five Factor H-Related proteins (FHR1-5). Using a targeted mass spectrometry approach, we quantified these proteins in a cohort of 188 plasma samples from controls and SARS-CoV-2 patients taken at diagnosis. This analysis revealed significant elevations in all FHR proteins, but not FH, in patients with more severe disease, particularly FHR2 and FHR5 (FHR2: 1.97-fold, p<0.0001; FHR5: 2.4-fold, p<0.0001). Furthermore, for a subset of 77 SARS-CoV-2 +ve patients we also analysed time course samples taken approximately 28 days post-diagnosis. Here, we see complement regulator levels drop in all individuals with asymptomatic or mild disease, but regulators remain high in those with more severe outcomes, with elevations in FHR2 over baseline levels in this group. These data support the hypothesis that elevation of circulating levels of the FHR family of proteins could predict disease severity in COVID-19 patients, and that the duration of elevation (or lack of immune activation resolution) may be partly responsible for driving poor outcomes in COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a complement | |
| 650 | 4 | |a factor H | |
| 650 | 4 | |a factor H-related proteins | |
| 650 | 4 | |a mass spectrometry | |
| 650 | 7 | |a Complement Factor H |2 NLM | |
| 650 | 7 | |a 80295-65-4 |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 700 | 1 | |a Alali, Wajd Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Rees-Unwin, Karen S |e verfasserin |4 aut | |
| 700 | 0 | |a CITIID-NIHR BioResource COVID-19 Collaboration |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Simon J |e verfasserin |4 aut | |
| 700 | 1 | |a Unwin, Richard D |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Bradley, John |e investigator |4 oth | |
| 700 | 1 | |a Chinnery, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Cooper, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Dougan, Gordon |e investigator |4 oth | |
| 700 | 1 | |a Goodfellow, Ian |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Ravindra |e investigator |4 oth | |
| 700 | 1 | |a Kingston, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Lehner, Paul J |e investigator |4 oth | |
| 700 | 1 | |a Lyons, Paul A |e investigator |4 oth | |
| 700 | 1 | |a Matheson, Nicholas J |e investigator |4 oth | |
| 700 | 1 | |a Saunders, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Smith, Kenneth G C |e investigator |4 oth | |
| 700 | 1 | |a Summers, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Thaventhiran, James |e investigator |4 oth | |
| 700 | 1 | |a Torok, M Estee |e investigator |4 oth | |
| 700 | 1 | |a Toshner, Mark R |e investigator |4 oth | |
| 700 | 1 | |a Weekes, Michael P |e investigator |4 oth | |
| 700 | 1 | |a Alvio, Gisele |e investigator |4 oth | |
| 700 | 1 | |a Baker, Sharon |e investigator |4 oth | |
| 700 | 1 | |a Bermperi, Areti |e investigator |4 oth | |
| 700 | 1 | |a Brookes, Karen |e investigator |4 oth | |
| 700 | 1 | |a Bucke, Ashlea |e investigator |4 oth | |
| 700 | 1 | |a Calder, Jo |e investigator |4 oth | |
| 700 | 1 | |a Canna, Laura |e investigator |4 oth | |
| 700 | 1 | |a Crucusio, Cherry |e investigator |4 oth | |
| 700 | 1 | |a Cruz, Isabel |e investigator |4 oth | |
| 700 | 1 | |a de Jesus, Ranalie |e investigator |4 oth | |
| 700 | 1 | |a Dempsey, Katie |e investigator |4 oth | |
| 700 | 1 | |a Di Stephano, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Domingo, Jason |e investigator |4 oth | |
| 700 | 1 | |a Elmer, Anne |e investigator |4 oth | |
| 700 | 1 | |a Harris, Julie |e investigator |4 oth | |
| 700 | 1 | |a Hewitt, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Jones, Heather |e investigator |4 oth | |
| 700 | 1 | |a Jose, Sherly |e investigator |4 oth | |
| 700 | 1 | |a Kennet, Jane |e investigator |4 oth | |
| 700 | 1 | |a King, Yvonne |e investigator |4 oth | |
| 700 | 1 | |a Kourampa, Jenny |e investigator |4 oth | |
| 700 | 1 | |a Li, Emily |e investigator |4 oth | |
| 700 | 1 | |a McMahon, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Meadows, Anne |e investigator |4 oth | |
| 700 | 1 | |a Mendoza, Vivien |e investigator |4 oth | |
| 700 | 1 | |a O'Brien, Criona |e investigator |4 oth | |
| 700 | 1 | |a Ocaya, Charmain |e investigator |4 oth | |
| 700 | 1 | |a Pasquale, Ciro |e investigator |4 oth | |
| 700 | 1 | |a Perales, Marlyn |e investigator |4 oth | |
| 700 | 1 | |a Price, Jane |e investigator |4 oth | |
| 700 | 1 | |a Rastall, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Ribeiro, Carla |e investigator |4 oth | |
| 700 | 1 | |a Rowlands, Jane |e investigator |4 oth | |
| 700 | 1 | |a Ruffolo, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Tordesillas, Hugo |e investigator |4 oth | |
| 700 | 1 | |a Vargas, Phoebe |e investigator |4 oth | |
| 700 | 1 | |a Vergese, Bensi |e investigator |4 oth | |
| 700 | 1 | |a Watson, Laura |e investigator |4 oth | |
| 700 | 1 | |a Worsley, Jieniean |e investigator |4 oth | |
| 700 | 1 | |a Zerrudo, Julie-Ann |e investigator |4 oth | |
| 700 | 1 | |a Bergamashi, Laura |e investigator |4 oth | |
| 700 | 1 | |a Betancourt, Ariana |e investigator |4 oth | |
| 700 | 1 | |a Bower, Georgie |e investigator |4 oth | |
| 700 | 1 | |a Bullman, Ben |e investigator |4 oth | |
| 700 | 1 | |a Cossetti, Chiara |e investigator |4 oth | |
| 700 | 1 | |a De Sa, Aloka |e investigator |4 oth | |
| 700 | 1 | |a Dunmore, Benjamin J |e investigator |4 oth | |
| 700 | 1 | |a Epping, Maddie |e investigator |4 oth | |
| 700 | 1 | |a Fawke, Stuart |e investigator |4 oth | |
| 700 | 1 | |a Gräf, Stefan |e investigator |4 oth | |
| 700 | 1 | |a Grenfell, Richard |e investigator |4 oth | |
| 700 | 1 | |a Hinch, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Hodgson, Josh |e investigator |4 oth | |
| 700 | 1 | |a Huang, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Huhn, Oisin |e investigator |4 oth | |
| 700 | 1 | |a Hunter, Kelvin |e investigator |4 oth | |
| 700 | 1 | |a Jarvis, Isobel |e investigator |4 oth | |
| 700 | 1 | |a Jones, Emma |e investigator |4 oth | |
| 700 | 1 | |a Josipović, Maša |e investigator |4 oth | |
| 700 | 1 | |a Legchenko, Ekaterina |e investigator |4 oth | |
| 700 | 1 | |a Lewis, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Marsden, Joe |e investigator |4 oth | |
| 700 | 1 | |a Martin, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Mescia, Federica |e investigator |4 oth | |
| 700 | 1 | |a O'Donnell, Ciara |e investigator |4 oth | |
| 700 | 1 | |a Omarjee, Ommar |e investigator |4 oth | |
| 700 | 1 | |a Perera, Marianne |e investigator |4 oth | |
| 700 | 1 | |a Pointon, Linda |e investigator |4 oth | |
| 700 | 1 | |a Pond, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Richoz, Nathan |e investigator |4 oth | |
| 700 | 1 | |a Romashova, Nika |e investigator |4 oth | |
| 700 | 1 | |a Savoinykh, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Sharma, Rahul |e investigator |4 oth | |
| 700 | 1 | |a Shih, Joy |e investigator |4 oth | |
| 700 | 1 | |a Strezlecki, Mateusz |e investigator |4 oth | |
| 700 | 1 | |a Sutcliffe, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Tilly, Tobias |e investigator |4 oth | |
| 700 | 1 | |a Tong, Zhen |e investigator |4 oth | |
| 700 | 1 | |a Treacy, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Turner, Lori |e investigator |4 oth | |
| 700 | 1 | |a Wood, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Wylot, Marta |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022) vom: 04., Seite 1032331 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:04 |g pages:1032331 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.1032331 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 04 |h 1032331 | ||